Src Is a Potential Therapeutic Target in Endocrine-Resistant Breast Cancer Exhibiting Low Estrogen Receptor-Mediated Transactivation

Gene Signature-Guided Dasatinib Therapy in Metastatic Breast Cancer

(2014) L. Pusztai et al.   CLINICAL CANCER RESEARCH

Dasatinib-Letrozole Gets Split Verdict

(2014)   Cancer Discovery

A transformation in the mechanism by which the urokinase receptor signals provides a selection advantage for estrogen receptor-expressing breast cancer cells in the absence of estrogen

(2012) Boryana M. Eastman et al.   CELLULAR SIGNALLING

ERα Phosphorylation at Y537 by Src Triggers E6-AP-ERα Binding, ERα Ubiquitylation, Promoter Occupancy, and Target Gene Expression

(2012) Jun Sun et al.   MOLECULAR ENDOCRINOLOGY

Tyrosine phosphorylation of estradiol receptor by Src regulates its hormone-dependent nuclear export and cell cycle progression in breast cancer cells

(2012) G Castoria et al.   ONCOGENE

Src: a potential target for the treatment of triple-negative breast cancer

(2011) D. Tryfonopoulos et al.   ANNALS OF ONCOLOGY

The role of caveolin-1 in human breast cancer

(2011) Neill Patani et al.   BREAST CANCER RESEARCH AND TREATMENT

Dasatinib as a Single Agent in Triple-Negative Breast Cancer: Results of an Open-Label Phase 2 Study

(2011) R. S. Finn et al.   CLINICAL CANCER RESEARCH

A Phase 2 Trial of Dasatinib in Patients with Advanced HER2-Positive and/or Hormone Receptor-Positive Breast Cancer

(2011) E. L. Mayer et al.   CLINICAL CANCER RESEARCH

Phase II Trial of Dasatinib in Patients with Metastatic Breast Cancer Using Real-Time Pharmacodynamic Tissue Biomarkers of Src Inhibition to Escalate Dosing

(2011) Christina I. Herold et al.   CLINICAL CANCER RESEARCH

Global quantification of mammalian gene expression control

(2011) Björn Schwanhäusser et al.   NATURE

The interaction between caveolin-1 and Rho-GTPases promotes metastasis by controlling the expression of alpha5-integrin and the activation of Src, Ras and Erk

(2011) E Arpaia et al.   ONCOGENE

Significance of ER–Src axis in hormonal therapy resistance

(2010) Sreeram Vallabhaneni et al.   BREAST CANCER RESEARCH AND TREATMENT

Dasatinib reduces FAK phosphorylation increasing the effects of RPI-1 inhibition in a RET/PTC1-expressing cell line

(2010) Dario Caccia et al.   Molecular Cancer

Development of Candidate Genomic Markers to Select Breast Cancer Patients for Dasatinib Therapy

(2010) S. Moulder et al.   MOLECULAR CANCER THERAPEUTICS

Growth of hormone-dependent MCF-7 breast cancer cells is promoted by constitutive caveolin-1 whose expression is lost in an EGF-R-mediated manner during development of tamoxifen resistance

(2009) Nicholas B. P. Thomas et al.   BREAST CANCER RESEARCH AND TREATMENT

Activity of the multikinase inhibitor dasatinib against ovarian cancer cells

(2009) G E Konecny et al.   BRITISH JOURNAL OF CANCER

PELP1: A novel therapeutic target for hormonal cancers

(2009) Dimple Chakravarty et al.   IUBMB LIFE

Effects of Src kinase inhibition induced by dasatinib in non-small cell lung cancer cell lines treated with cisplatin

(2009) P. Ceppi et al.   MOLECULAR CANCER THERAPEUTICS

ERBB2 influences the subcellular localization of the estrogen receptor in tamoxifen-resistant MCF-7 cells leading to the activation of AKT and RPS6KA2

(2008) S. Pancholi et al.   ENDOCRINE-RELATED CANCER

PELP1—A novel estrogen receptor-interacting protein

(2008) Darrell W. Brann et al.   MOLECULAR AND CELLULAR ENDOCRINOLOGY

MNAR plays an important role in ERa activation of Src/MAPK and PI3K/Akt signaling pathways

(2008) B CHESKIS et al.   STEROIDS